Becton, Dickinson and Co.

BDX

Becton, Dickinson and Co. (BDX) is a global medical technology company specializing in the development and manufacturing of medical devices, supplies, and laboratory equipment. Founded in 1897, it is known for its innovations in healthcare including syringes, safety-engineered devices, and diagnostic products, serving healthcare institutions, life sciences, and general medical markets worldwide.

$206.04 0.00 (0.00%)
Dividend Yield 2.02%
Payout Frequency Quarterly

Dividend History

Pay DateAmountEx-DateRecord Date
December 31, 2025$1.052025-12-082025-12-08
September 30, 2025$1.042025-09-082025-09-08
June 30, 2025$1.042025-06-092025-06-09
March 31, 2025$1.042025-03-102025-03-10
December 31, 2024$1.042024-12-092024-12-09

Dividends Summary

Company News

Anatomic Pathology Market Research: Global and Regional Insights, Competition, Forecast and Opportunities, 2025-2033 | Astute Analytica
GlobeNewswire Inc. • Astute Analytica • January 22, 2026

The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology i...

Atherectomy Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036
GlobeNewswire Inc. • Researchandmarkets.Com • January 16, 2026

A comprehensive market analysis report on atherectomy devices covering 39 countries with forecasts through 2036. The market is driven by the shift toward minimally-invasive techniques for treating coronary and peripheral artery diseases, replacing traditional bypass surgery. The report provides detailed market segmentation, intervention volumes, ...

Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
Benzinga • Vandana Singh • January 15, 2026

Becton, Dickinson and Company received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, with market launch expected in early 2026. The advanced system features high and low vacuum strengths, 360-degree sampling ability, and multiple probe options. However, analysts expect slightly lower earnings and revenue co...

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider
GlobeNewswire Inc. • Sns Insider • January 12, 2026

The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North Ame...

Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst
Benzinga • Vandana Singh • January 6, 2026

William Blair initiated Outperform coverage on Waters Corporation following its merger with Becton Dickinson's Biosciences & Diagnostic Solutions business. The analyst sees greater synergy upside than initially priced in, with EPS accretion of ~$0.10 in 2026 rising to ~$2.70 by 2028. William Blair projects roughly 20% upside by year-end 2026 and ...

Related Companies